Tags : RCC

Biotech

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives

Shots: The approval is based on P-III CheckMate-214 study results assessing Opdivo (3mg/kg) + low-dose Yervoy(1mg/kg) vs sunitinib (50mg, qd) in patients with previously untreated advance RCC P-III Checkmate-214 study results: ORR (41.6% vs 26.5%); CRR (9.4% vs 1.2%); Grade 3 or 4 adverse events (65% vs 76%) Opdivo (nivolumab) is a programmed death-1 (PD-1) […]Read More